VSTM logo

VSTM
Verastem Inc

24,063
Mkt Cap
$430.83M
Volume
852,054.00
52W High
$11.25
52W Low
$4.01
PE Ratio
-1.34
VSTM Fundamentals
Price
$5.72
Prev Close
$5.72
Open
$5.63
50D MA
$6.77
Beta
1.33
Avg. Volume
2.06M
EPS (Annual)
-$3.66
P/B
-24.59
Rev/Employee
$128,205.13
$138.07
Loading...
Loading...
News
all
press releases
Verastem (VSTM) Projected to Post Earnings on Wednesday
Verastem (NASDAQ:VSTM) will be releasing its Q4 2025 earnings after the market closes on Wednesday, March 4. (View Earnings Report at...
MarketBeat·5d ago
News Placeholder
More News
News Placeholder
Verastem Oncology to Report Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026
Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the Company will host a...
Business Wire·11d ago
News Placeholder
What Makes Verastem (VSTM) a New Buy Stock
Verastem (VSTM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Zacks·12d ago
News Placeholder
Verastem Touts 50%+ Sales Growth for LGSOC Launch, Teases RAMP 301 and KRAS G12D Catalysts
Verastem (NASDAQ:VSTM) executives highlighted commercial momentum for the company's newly launched ovarian cancer therapy and laid out near-term clinical catalysts across its RAS-pathway pipeline...
MarketBeat·14d ago
News Placeholder
FY2025 EPS Estimates for Verastem Increased by HC Wainwright
Verastem, Inc. (NASDAQ:VSTM - Free Report) - Equities research analysts at HC Wainwright increased their FY2025 earnings estimates for Verastem in a note issued to investors on Thursday, February...
MarketBeat·21d ago
News Placeholder
Verastem, Inc. (NASDAQ:VSTM) Receives Consensus Rating of "Moderate Buy" from Brokerages
Shares of Verastem, Inc. (NASDAQ:VSTM - Get Free Report) have received an average recommendation of "Moderate Buy" from the ten research firms that are covering the company, Marketbeat.com reports...
MarketBeat·22d ago
News Placeholder
HC Wainwright Forecasts Verastem FY2025 Earnings
Verastem, Inc. (NASDAQ:VSTM - Free Report) - Equities research analysts at HC Wainwright issued their FY2025 EPS estimates for shares of Verastem in a report released on Wednesday, February 4th. HC...
MarketBeat·24d ago
News Placeholder
Verastem Stock Rises Nearly 8% on Strong Q4 & 2025 Preliminary Results
VSTM shares rise nearly 8% after the release of preliminary fourth-quarter 2025 and full-year 2025 sales numbers, driven by Avmapki Fakzynja Co-pack.
Zacks·24d ago
News Placeholder
HC Wainwright Estimates Verastem FY2030 Earnings
Verastem, Inc. (NASDAQ:VSTM - Free Report) - Research analysts at HC Wainwright issued their FY2030 earnings per share estimates for shares of Verastem in a research note issued on Wednesday...
MarketBeat·25d ago
News Placeholder
$668B Oncology Surge: 5 Platforms Cracking the Code on GI Tumors
$668B Oncology Surge: 5 Platforms Cracking the Code on GI Tumors $668B Oncology Surge: 5 Platforms Cracking the Code on GI Tumors PR Newswire VANCOUVER, BC, Jan. 30, 2026 Issued on behalf of...
PR Newswire·1mo ago
<
1
2
...
>

Latest VSTM News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.